Tenderwize
Zurück zur Suche

Non-exclusive discount agreement for Zolmitriptan (ATC N02CC03)

AOK Niedersachsen. Die Gesundheitskasse.·Hannover, Germany·Deadline Mar 27, 2027 · 214 days left·Open·Supplies·Framework
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Zolmitriptan (ATC N02CC03).

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

50 / 100

Komplexität

20 / 100

Risikofaktoren

Open-house contracts will be automatically terminated when exclusive discount agreements are awarded. This can happen a...

Electronic submission is not allowed; only paper submission is accepted. This increases administrative burden and risk...

No procurement documents available

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Conclusion of non-exclusive discount agreements for pharmaceutical products with active substance Zolmitriptan (ATC N02CC03)
  • Open-house model: all interested and eligible pharmaceutical companies may participate without selection
Vollständige Zusammenfassung anzeigen

This is a non-exclusive discount agreement ('open-house model') under § 130a Abs. 8 SGB V for pharmaceuticals containing Zolmitriptan (ATC N02CC03). The AOK Niedersachsen invites all interested pharmaceutical companies to conclude discount agreements without a competitive selection. The agreement period runs from 01 June 2025 to 31 May 2027, with contracts possible at any time during this period. The open-house agreements will be replaced automatically when exclusive discount contracts are awarded (expected 6-8 months after publication of a call for competition). The procedure is not a public contract under EU procurement law; the publication is for transparency purposes. Submission deadlines apply for initial contracts (24 April 2025) and later for monthly join dates. Electronic submission is not allowed; paper submission is required.

Risiken

Open-house contracts will be automatically terminated when exclusive discount agreements are awarded. This can happen a...

Electronic submission is not allowed; only paper submission is accepted. This increases administrative burden and risk...

No procurement documents available

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical entrepreneur within the meaning of § 4 Abs. 18 AMG or a consortium of such
  • Pharmaceutical products must be authorised for market in Germany under AMG
  • The pharmaceutical entrepreneur must have its registered office within Germany, EU, or EEA (§ 9 Abs. 2 Satz 1 AMG)

Anforderungen können unvollständig sein.

Zuschlagskriterien

Lot 1

Price (discount) criterion; uniform conditions apply to all participants.

Auftraggeber

Lose (1)

LOT-0000

Non-exclusive discount agreement for Zolmitriptan (ATC N02CC03)

Open-house model for Zolmitriptan (ATC N02CC03) discount agreements. All eligible pharmaceutical companies may join under uniform conditions. Contracts are non-exclusive and will be replaced by exclusive agreements once awarded.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE929, Germany

Dauer

May 2025 - May 2027

Kategorie

Pharmaceutical products

Zuschlagskriterien

Price

Frist

Deadline Mar 27, 2027

Vergabedetails

Veröffentlichungsdatum
31 Mar 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
207292-2025

Ähnliche Ausschreibungen